Home/iOnctura/Lars van der Veen
LV

Lars van der Veen

Co-Founder, Chief Scientific Officer

iOnctura

Therapeutic Areas

iOnctura Pipeline

DrugIndicationPhase
Roginolisib (IOA-244)Oncology (unspecified)Phase 2
Cambritaxestat (IOA-289)Oncology (unspecified)Phase 2
IOA-359Oncology (unspecified)Phase 1